
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. has demonstrated significant growth in its TissueCypher test, with test volume increasing by 92% year-over-year and 23% quarter-over-quarter in the second quarter of 2025, indicating strong market demand and effective sales force expansion. The company has also successfully improved the gross margin for the TissueCypher test, reporting an impressive 77% in the third quarter, which reflects operational efficiencies and profitability potential. With most of the gastrointestinal sales force expected to reach maturity in the second half of 2025, the outlook for continued revenue growth in this segment appears optimistic.
Bears say
Castle Biosciences Inc. faces a challenging outlook as its EV-to-estimated 2026/2027 revenue multiples for its dermatology and DecisionDx-UM tests are projected to be significantly lower than those for TissueCypher, indicating potential revenue pressures. A lack of clinician awareness, particularly within the gastroenterology sector, is identified as a major roadblock, suggesting that the company is struggling to penetrate the market effectively. Despite indications that the stock is undervalued from a conservative perspective, the fundamental concerns around market penetration and revenue generation raise doubts about its growth potential in the near term.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares